Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Yu Lu, Ying Liu, Shupeng Wen, Na Kuang, Xuejun Zhang, Jianqiang Li, Fuxu WangJournal of Translational Medicine 2022 · DOI

TL;DR

Researchers have developed a novel CAR-T cell therapy that targets CD7, a protein found on acute myeloid leukemia (AML) cells but not on normal myeloid cells. This "naturally selected" CD7 CAR-T therapy, which avoids genetic editing, shows significant promise in preclinical studies for treating relapsed and refractory AML, offering a potentially safer and more cost-effective alternative to existing treatments.

What Problem Does This Paper Address?

Acute myeloid leukemia (AML) is a challenging blood cancer, particularly when it relapses or becomes refractory to standard treatments. While CAR-T cell therapy has shown success in other blood cancers, its application in AML faces hurdles. Current AML CAR-T therapies often target myeloid-lineage antigens like CD123 and CD33. However, these targets are also present on crucial hematopoietic stem cells, raising concerns about severe side effects like myelosuppression. The search for a more specific and safer target is critical. CD7, a protein expressed on T cells and NK cells, but importantly, not on normal myeloid cells, presents a promising alternative. This paper investigates the potential of CD7-targeted CAR-T cells, specifically exploring a "naturally selected" approach that bypasses the need for genetic modification of the CAR-T cells themselves.

Methods

The researchers employed a multi-pronged approach:

  • CD7 Expression Analysis: Immunohistochemistry and flow cytometry were used to assess CD7 expression in clinical samples from R/R-AML patients and healthy donors (HDs). This helped confirm CD7's presence on AML cells and its absence on normal myeloid cells.
  • CAR-T Cell Design and Generation: They designed and produced CD7 CAR-T cells using a lentiviral vector. A key aspect of their "naturally selected" approach is that the CAR-T cells themselves naturally lose CD7 expression by day 12 post-transduction, mitigating potential self-targeting issues.
  • In Vitro Assays:
    • Flow Cytometry: Used to analyze CAR expression, cell viability, and the expression of exhaustion markers (PD-1, TIM-3, LAG-3) on CAR-T cells. They also assessed T cell memory phenotypes (naïve, central memory, effector memory).
  • Cytotoxicity Assays: Evaluated the ability of CD7 CAR-T cells to kill various AML cell lines (including those engineered to overexpress CD7) and primary R/R-AML patient blasts.
  • Cytokine Secretion Assays: Measured the release of cytokines (IFN-γ, TNF-α, IL-2) by CAR-T cells upon encountering AML cells.
  • In Vivo Xenograft Model: A mouse model was established by injecting MOLM-13-GFP-luciferase AML cells. Mice were then treated with CD7 CAR-T cells, non-transduced T cells (NTR), or a vehicle control. Tumor growth was monitored using bioluminescence imaging (IVIS).

Datasets

The study utilized:

  • Clinical Samples: Bone marrow biopsy samples from 3 R/R-AML patients and peripheral blood mononuclear cells (PBMCs) from R/R-AML patients and healthy donors.
  • Cell Lines: Standard AML cell lines (KG-1a, MOLM-13, CCRF-CEM, K562) and a K562 cell line engineered to overexpress CD7 (K562-CD7).
  • Animal Model: A xenograft model using NOD-Prkdcscid-Il2rgem1 (NTG) mice injected with MOLM-13-GFP-Luc AML cells.

No new benchmark datasets were introduced.

Key Insights and Ideas

  • CD7 as a Promising Target: The study strongly reinforces CD7 as a viable target for AML CAR-T therapy due to its expression on AML cells and absence on normal myeloid cells, suggesting a reduced risk of on-target, off-tumor toxicity.
  • "Naturally Selected" CAR-T Cells: The concept of CAR-T cells that naturally downregulate their target antigen (CD7) post-transduction is a clever way to potentially avoid fratricide and improve safety without complex genetic engineering.
  • Memory Phenotype Advantage: CD7 CAR-T cells showed an enrichment in central memory T cell populations, which is crucial for long-term persistence and sustained anti-leukemic activity.
  • Preclinical Efficacy Confirmed: The combination of in vitro cytotoxicity and in vivo tumor suppression in a mouse model provides robust preclinical evidence for the therapeutic potential of this approach.

Key Results

  • CD7 Expression: Approximately 31.25% (5 out of 16) of R/R-AML patients with minimal residual disease (MRD) showed CD7 expression. CD7 was confirmed to be present on T cells but absent on normal myeloid cells in both R/R-AML patients and healthy donors.
  • CAR-T Cell Functionality:
    • Naturally selected CD7 CAR-T cells demonstrated high transduction rates and maintained viability above 78% even after 12 days.
  • In vitro, CD7 CAR-T cells effectively killed CD7+ AML cell lines and primary R/R-AML blasts across various effector-to-target ratios.
  • CD7 CAR-T cells induced significant secretion of IL-2 and IFN-γ upon encountering AML cells.
  • In the mouse xenograft model, CD7 CAR-T cell treatment led to a significant suppression of leukemia progression and a rapid decrease in tumor burden compared to control groups.
  • Memory Phenotype: CD7 CAR-T cells exhibited a higher proportion of central memory T cells (TCM) compared to non-transduced (NTR) T cells.
  • Exhaustion Markers: A trend towards increased PD-1 and TIM-3 expression was observed in CD7 CAR-T cells, though further validation is needed.

Limitations and Future Work

  • Preclinical Stage: The study is preclinical, and the efficacy and safety of this therapy need to be rigorously validated in human clinical trials.
  • CD7 Expression Variability: While CD7 is a promising target, its expression is not universal in AML, meaning this therapy would be most effective for CD7+ AML patients.
  • Exhaustion Markers: The observed increase in exhaustion markers (PD-1, TIM-3) warrants further investigation into their impact on long-term CAR-T cell function and persistence in vivo.
  • Durability: While in vitro persistence was suggested by memory phenotype analysis, further studies are needed to confirm long-term durability in comparison to other CAR-T strategies.
  • Clinical Trials: The authors emphasize the need for further clinical trials to assess the actual performance of CD7 CAR-T cells in R/R-AML patients and compare them to CD19 CAR-T cells. They also suggest exploring its use as a bridging therapy for allogeneic HSCT.

Summary updated

Abstract

Naturally selected CD7 CAR-T cells represent an effective treatment strategy for relapsed and refractory acute myeloid leukaemia patients in preclinical studies.
BibTeX
@article{lu2022naturally,
  author = {Yu Lu and Ying Liu and Shupeng Wen and Na Kuang and Xuejun Zhang and Jianqiang Li and Fuxu Wang},
  title = {{Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)}},
  journal = {Journal of Translational Medicine},
  year = {2022},
  doi = {10.1186/s12967-022-03797-7},
}
Figure